Evaluation of Heart Function in Breast Cancer Patients Using Trastuzumab

Evaluation of Heart Function in Breast Cancer Patients Using Trastuzumab

By dynamically observing the changes of echocardiogram and biomarkers in breast cancer patients using trastuzumab, evaluate the effect of trastuzumab on cardiac function; determine the sensitivity of echocardiography and biomarker indicators And specificity, explore effective and specific early warning indicators, and provide technical support for the evaluation of the cardiac safety of anti-tumor drugs.

Thirty female breast cancer patients using trastuzumab, collected demographic and clinical information of all patients before chemotherapy, performed echocardiography (conventional echocardiography, three-dimensional spot tracking technology), and collected blood samples to detect plasma biology Markers (TnT, BNP, GDF-15, topoisomerase), follow-up echocardiography and biomarkers at 1 month, 3 months and 6 months after chemotherapy.

Inclusion Criteria:

• Patients with breast cancer (18-70 years old)
• Patients who are planning to undergo trastuzumab for the first time

Exclusion Criteria:

• Organic heart disease such as coronary heart disease, heart valve disease, cardiomyopathy
• liver and kidney failure
• severe cerebrovascular disease
• chronic obstructive pulmonary disease
• rheumatic immune system disease
• other tumors